These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 37470319)
1. The efficacy of hyperthermic intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer patients with BCG intolerance. Akbulut F; Pazir Y; Esmeray A; Erbin A; Ozgor F; Sarilar O Urologia; 2023 Nov; 90(4):631-635. PubMed ID: 37470319 [TBL] [Abstract][Full Text] [Related]
2. Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis. Pazir Y; Esmeray A; Caglar U; Erbin A; Ozgor F; Sarilar O; Akbulut F Int Urol Nephrol; 2024 Mar; 56(3):957-963. PubMed ID: 37880493 [TBL] [Abstract][Full Text] [Related]
3. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. Guerrero-Ramos F; González-Padilla DA; González-Díaz A; de la Rosa-Kehrmann F; Rodríguez-Antolín A; Inman BA; Villacampa-Aubá F World J Urol; 2022 Apr; 40(4):999-1004. PubMed ID: 35037963 [TBL] [Abstract][Full Text] [Related]
4. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476 [TBL] [Abstract][Full Text] [Related]
5. HIVEC as an alternative option in non-muscle-invasive bladder cancer: Experiences from a high-volume center. Kastner L; Rieger C; Pfister D; Schmautz M; Storz E; Heidenreich A Urol Oncol; 2024 Aug; 42(8):245.e19-245.e26. PubMed ID: 38653592 [TBL] [Abstract][Full Text] [Related]
6. The Efficacy and Safety of Hyperthermia Intravesical Chemotherapy in the Treatment of Non-Muscle-Invasive Bladder Cancer: A Meta-Analysis. Duan H; Deng Z; Zou J; Zhang G; Zou X; Xie T Urol Int; 2024; 108(4):322-333. PubMed ID: 38508149 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure. Pignot G; Baboudjian M; Lebacle C; Chamouni A; Lechevallier E; Irani J; Tillou X; Waeckel T; Monges A; Doisy L; Walz J; Gravis G; Mourey E; Duperron C; Masson-Lecomte A World J Urol; 2023 Nov; 41(11):3195-3203. PubMed ID: 36811732 [TBL] [Abstract][Full Text] [Related]
8. Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer. Melgarejo Segura MT; Morales Martínez A; Yáñez Castillo Y; Arrabal Polo MÁ; Gómez Lechuga P; Pareja Vílchez M; Arrabal Martín M Urol Oncol; 2023 Feb; 41(2):109.e1-109.e8. PubMed ID: 36379812 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study. Arrabal Polo MÁ; Melgarejo Segura MT; Yáñez Castillo Y; Morales Martínez A; Pareja Vílchez M; Arrabal Martín M J Cancer Res Clin Oncol; 2023 Aug; 149(10):7453-7459. PubMed ID: 36952006 [TBL] [Abstract][Full Text] [Related]
10. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer. Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307 [TBL] [Abstract][Full Text] [Related]
11. Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage. Grimberg DC; Dudinec J; Shah A; Inman BA Urol Oncol; 2021 Aug; 39(8):498.e13-498.e20. PubMed ID: 33485761 [TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. Pijpers OM; Hendricksen K; Mostafid H; de Jong FC; Rosier M; Mayor N; de Jong JJ; Boormans JL Urol Oncol; 2022 Feb; 40(2):62.e13-62.e20. PubMed ID: 34470725 [TBL] [Abstract][Full Text] [Related]